余智祥,刘毅,易甫,陶凌,尹涛

• 1:空军军医大学第一附属医院心血管内科
• 2:空军军医大学基础学院

摘要(Abstract)：

<正>近些年,随着介入技术、器械和术者操作经验的提高,慢性完全闭塞(chronic total occlusion,CTO)病变行经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的成功率不断提升,一些有经验的术者成功率更是高达90%以上,已有越来越多的CTO患者接受PCI。EURO-CTO研究[1]显示CTO-PCI可以明显改善患者症状及生活质量。IRCTO研究[2]也证实CTO-PCI可以降低主要不良心血管事件(major adverse cardiovascular events,MACE)发生率。正是基于这些现有的循证医学证据,国内外PCI指南已将CTO-PCI列为Ⅱa类推荐[3-5]。然而,冠状动脉完全闭塞后长期缺血会导致部分心肌坏死或处于冬眠状态,导致心功能下降。CTO病变合并严重心功能不全,即左心室射血分数(left

关键词(KeyWords)： 心功能不全;慢性完全闭塞;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 余智祥,刘毅,易甫,陶凌,尹涛

参考文献(References)：

• [1] Werner GS, Martin-Yuste V, Hildick-Smith D,et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J, 2018,39(26):2484-2493.
• [2] Tomasello SD, Boukhris M,Giubilato S, et al. Management strategies in patients affected by chronic total occlusions:results from the Italian Registry of Chronic Total Occlusions. Eur Heart J,2015,36(45):3189-3198.
• [3]丛广志，贾绍斌.是否开通慢性完全闭塞病变？——关于DECISION-CTO试验的思考.中国介入心脏病学杂志，2018,26(4):230-232.
• [4] Galassi AR, Brilakis ES, Boukhris M,et al. Appropriateness of percutaneous revascularization of coronary chronic total occlusions:an overview. Eur Heart J, 2016, 37(35):2692-2700.
• [5]中华医学会心血管病学分会介入心脏病学组，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012（简本）.中华心血管病杂志，2012,40(4):271-277.
• [6] Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions:the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol, 2012,59(11):991-997.
• [7] Megaly M, Saad M, Tajti P,et al. Meta-analysis of the impact of successful chronic total occlusion percutaneous coronary intervention on left ventricular systolic function and reverse remodeling. J Interv Cardiol, 2018,31(5):562-571.
• [8] Henriques JP, Hoebers LP, Rfimunddal T, et al. Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI:the EXPLORE trial. J Am Coll Cardiol, 2016, 68(15):1622-1632.
• [9] Mashayekhi K, Nührenberg TG, Toma A, et al. A randomized trial to assess regional left ventricular function after stent implantation in chronic total occlusion:the REVASC trial. JACC Cardiovasc Interv, 2018, 11(19):1982-1991.
• [10] Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med,2016, 374(16):1511-1520.
• [11] Lfiffler AI, Kramer CM. Myocardial viability testing to guide coronary revascularization. Interv Cardiol Clin, 2018, 7(3):355-365.
• [12] Henzlova MJ, Duvall WL, Einstein AJ, et al. ASNC imaging guidelines for SPECT nuclear cardiology procedures:stress,protocols, and tracers. J Nucl Cardiol, 2016, 23(3):606-639.
• [13] Beanlands RS, Nichol G, Huszti E,et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease:a randomized, controlled trial(PARR-2). J Am Coll Cardiol, 2007, 50(20):2002-2012.
• [14] Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction:inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging, 2013, 6(3):363-372.
• [15] Swinburn JM, Lahiri A, Senior R. Intravenous myocardial contrast echocardiography predicts recovery of dysynergic myocardium early after acute myocardial infarction. J Am Coll Cardiol, 2001, 38(1):19-25.
• [16]栗佳男，张丽君，贺毅，等.心脏磁共振成像诊断冠状动脉慢性完全闭塞病变心肌活性的研究进展.中国介入心脏病学杂志，2017,25(9):525-527.
• [17] Karamitsos TD, Dall'Armellina E, Choudhury RP,et al. Ischemic heart disease:comprehensive evaluation by cardiovascular magnetic resonance. Am Heart J, 2011,162(1):16-30.
• [18] Schwitter J, Arai AE. Assessment of cardiac ischaemia and viability:role of cardiovascular magnetic resonance. Eur Heart J,2011, 32(7):799-809.
• [19] Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation, 1999, 100(19):1992-2002.
• [20] Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med, 2000, 343(20):1445-1453.
• [21] Baks T, van Geuns RJ, Duncker DJ,et al. Prediction of left ventricular function after drug-eluting stent implantation for chronic total coronary occlusions. J Am Coll Cardiol, 2006, 47(4):721-725.
• [22] Kirschbaum SW, Baks T, van den Ent M, et al. Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions. Am J Cardiol, 2008, 101(2):179-185.
• [23] Kirschbaum SW, Rossi A, van Domburg RT,et al. Contractile reserve in segments with nontransmural infarction in chronic dysfunctional myocardium using low-dose dobutamine CMR. JACC Cardiovasc Imaging, 2010, 3(6):614-622.
• [24] Romero J, Xue X, Gonzalez W, et al. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease:a meta-analysis of prospective trials. JACC Cardiovasc Imaging, 2012, 5(5):494-508.
• [25] Tamburino C, Capranzano P, Capodanno D,et al. Percutaneous recanalization of chronic total occlusions:wherein lies the body of proof? Am Heart J, 2013, 165(2):133-142.
• [26] Kar, S. Percutaneous mechanical circulatory support devices for high-risk percutaneous coronary intervention. Curr Cardiol Rep,2018, 20(1):2.
• [27] Myat A, Patel N, Tehrani S,et al. Percutaneous circulatory assist devices for high-risk coronary intervention. JACC Cardiovasc Interv, 2015, 8(2):229-244.
• [28] Vetrovec GW. Hemodynamic support devices for shock and high-risk pci:when and which one. Curr Cardiol Rep, 2017, 19(10):100.
• [29] Perera D, Stables R, Thomas M, et al. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention:a randomized controlled trial. JAMA, 2010, 304(8):867-874.
• [30] Perera D, Stables R, Clayton T, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study(BCIS-1):a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention.Circulation, 2013, 127(2):207-212.
• [31] Kovacic JC, Kini A, Banerjee S,et al. Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump:a sub-study of the PROTECT II trial. J Interv Cardiol, 2015, 28(1):32-40.